Table 1.
Breast cancer anatomopathological surrogate definitions based on immunohistochemical subtyping methods.
| Definition marker | Luminal A-like | Luminal B-like (HER2 negative) | Luminal B-like (HER2 positive) | HER2 positive (non-luminal) | Triple negative (ductal) |
|---|---|---|---|---|---|
| Erb-B2 | –* | –* | +* | +* | –* |
| ER | + | + | + | – | – |
| PR | + | –/↓ | + | – | – |
| Other relevant | Ki-67↓ | Ki-67↑ | Ki-67 | Cytokeratins** | |
| Prevalence | 30~70% | 10~20% | 10~20% | 15~25% | |
| Main treatment strategy | Endocrine therapy | Endocrine therapyCytotoxic | anti-HER2 Cytotoxic | Cytotoxic | |
| Recurrence Risk | ↓ | ↑ | ↓ | ↑↑ | |
| SIRT1 | ~74% | ~55% | ~42% | ||
Concurrent marker detection is achieved for establishing subtypes. Not mentioned minor special histological types may respond to targeted therapies. Erb-B2, human epidermal growth factor receptor 2 (HER2);
*
overexpressed or amplified; ER, Estrogen Receptor; PR, Progesterone Receptor; Ki-67, proliferation marker; Cytokeratins, basal-like marker (8–14).
**
highly overexpressed; ↓low expression/risk; ↑high expression/risk; ↑↑very high expression/risk.